ANEB
Anebulo Pharmaceuticals, Inc. [ANEB] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
ANEB Stock Summary
Top 10 Correlated ETFs
ANEB
Top 10 Correlated Stocks
ANEB
In the News
ANEB Financial details
Company Rating
-
Market Cap
75.34M
Income
-10.43M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
2
Optionable
No
Shortable
Yes
Earnings
09 May 2024
P/E
-5.37
Forward P/E
-
PEG
-1.25
P/S
-
P/B
7.45
P/C
-
P/FCF
-5.98
Quick Ratio
11.89
Current Ratio
12.63
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.41
EPS next Y
-
EPS next Q
-
EPS this Y
62.07%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
13.64%
-
-
-
-
SMA20
-32.9%
SMA50
-56.85%
SMA100
-59.06%
Inst Own
-
Inst Trans
-
ROA
-128%
ROE
-97%
ROC
-1.41%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
1.62-4.05
52W High
-78.63%
52W Low
-14.51%
RSI
22.23
Rel Volume
9.5
Avg Volume
5.69K
Volume
54.04K
Perf Week
-21.57%
Perf Month
-62.67%
Perf Quarter
-68.34%
Perf Half Y
-72.77%
-
-
-
-
Beta
-1.005
-
-
Volatility
0.09%, 0.44%
Prev Close
-6.07%
Price
0.8549
Change
-13.65%
Company Profile
- Volume Average 5.69K
- Market Capitalization 75.34M
- Employee 2
- CEO Mr. Richard Anthony Cunningham
- Headquarters Lakeway,TX,US
- IPO Date 2021-05-07
-
Website
https://www.anebulo.com 
Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing and commercializing treatments for people suffering from acute cannabinoid intoxication and substance addiction. Its lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist to treat cannabinoid intoxication and overdose. The company was incorporated in 2020 and is based in Lakeway, Texas.
